TRT Gel denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt gel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Testosterone Gel as Non-Formulary

A non-formulary denial means testosterone gel in its specific brand or formulation is not included on UHC's active drug formulary for your plan. UHC maintains tiered formularies that change annually, and topical testosterone products may appear on a restricted tier or be absent entirely in favor of a formulary-preferred alternative. This is one of the most routinely overturned denial types because federal and state law provide strong exception pathways.

## Your Federal Appeal Rights

• Formulary exception / internal appeal: File a formulary exception request alongside your internal appeal under ERISA §503. You have 180 days from the denial. UHC must respond within 30 days (72 hours expedited).
• External review (ACA §2719): After exhausting the internal process, you may escalate to an independent review organization within approximately four months of final denial. The IRO's ruling is binding.
• Expedited track: Request expedited processing if delay creates a significant health risk.

## The Core Argument: Medical Necessity for This Formulation

A non-formulary exception is granted when the formulary alternatives are clinically inappropriate for you specifically. Your appeal should demonstrate — through your prescriber's letter — why the formulary-preferred alternative(s) cannot be substituted. Common clinical reasons include documented skin-sensitivity or absorption differences, prior failure of the preferred alternative, or a patient-specific medical condition that makes the non-formulary product the appropriate choice per the FDA-approved prescribing label.

## What to Gather

1. Prescriber's formulary-exception letter — explicitly addresses each formulary alternative and explains why each is clinically contraindicated or inappropriate for this patient. 2. Trial-and-failure records — if you previously tried a formulary-preferred product, provide dates, dosing period, and documented outcome or adverse response. 3. Diagnosis and lab confirmation — same core documents as a medical-necessity appeal (confirmed hypogonadism diagnosis, symptom records). 4. FDA label reference — your prescriber's letter should reference the product's FDA-approved prescribing information to anchor the medical rationale. 5. Applicable guideline citation — reference the relevant Endocrine Society guideline generically as support for individualized formulation selection.

## Criteria-Mapping Structure

Obtain UHC's formulary exception policy (published on the UHC member portal or plan documents). Build a two-column response:

| Exception Criterion | Your Evidence | |---|---| | Formulary alternative tried and failed | [Record date, product, outcome] | | Formulary alternative clinically inappropriate | [Prescriber letter, clinical rationale] | | Medical necessity of requested product | [Prescriber letter, guideline reference] |

Attach the completed table as an exhibit to your appeal letter. A peer-to-peer call between your prescriber and UHC's pharmacy medical director is highly effective for non-formulary exceptions — ask for one explicitly in your appeal.